Cargando…

The 4-aminopiperidine series has limited anti-tubercular and anti-staphylococcus aureus activity

BACKGROUND: Tuberculosis (TB) caused by Mycobacterium tuberculosis is the leading cause of death from a bacterial infection. The 4-aminopiperidine (PIP) series has been reported as having anti-bacterial activity against M. tuberculosis. We explored this series for its potential to inhibit aerobic gr...

Descripción completa

Detalles Bibliográficos
Autores principales: Chandrasekera, N Susantha, Alling, Torey, Bailey, Mai, Korkegian, Aaron, Ahn, James, Ovechkina, Yulia, Odingo, Joshua, Parish, Tanya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4336482/
https://www.ncbi.nlm.nih.gov/pubmed/25881065
http://dx.doi.org/10.1186/s12952-015-0024-x
_version_ 1782358475553112064
author Chandrasekera, N Susantha
Alling, Torey
Bailey, Mai
Korkegian, Aaron
Ahn, James
Ovechkina, Yulia
Odingo, Joshua
Parish, Tanya
author_facet Chandrasekera, N Susantha
Alling, Torey
Bailey, Mai
Korkegian, Aaron
Ahn, James
Ovechkina, Yulia
Odingo, Joshua
Parish, Tanya
author_sort Chandrasekera, N Susantha
collection PubMed
description BACKGROUND: Tuberculosis (TB) caused by Mycobacterium tuberculosis is the leading cause of death from a bacterial infection. The 4-aminopiperidine (PIP) series has been reported as having anti-bacterial activity against M. tuberculosis. We explored this series for its potential to inhibit aerobic growth of M. tuberculosis. We examined substitution at the N-1 position and C-4 position of the piperidine and modifications of the piperidine moiety systematically to delineate structure-activity relationships influencing potency. Compounds were tested for growth-inhibitory activity against virulent M. tuberculosis. A selected set of compounds were also tested for its activity against Staphylococcus aureus. RESULTS: The compound with a norbornenylmethyl substituent at the N-1 position and N-benzyl-N-phenethylamine at the C-4 position of the piperidine (1) was the only active compound with a minimum inhibitory concentration (MIC) of 10 μM against M. tuberculosis. Compounds were not active against S. aureus. CONCLUSIONS: We were unable to derive any other analogs with MIC < 20 μM against M. tuberculosis. Therefore we conclude that the lack of activity is a liability in this series precluding it from further development.
format Online
Article
Text
id pubmed-4336482
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-43364822015-02-22 The 4-aminopiperidine series has limited anti-tubercular and anti-staphylococcus aureus activity Chandrasekera, N Susantha Alling, Torey Bailey, Mai Korkegian, Aaron Ahn, James Ovechkina, Yulia Odingo, Joshua Parish, Tanya J Negat Results Biomed Research BACKGROUND: Tuberculosis (TB) caused by Mycobacterium tuberculosis is the leading cause of death from a bacterial infection. The 4-aminopiperidine (PIP) series has been reported as having anti-bacterial activity against M. tuberculosis. We explored this series for its potential to inhibit aerobic growth of M. tuberculosis. We examined substitution at the N-1 position and C-4 position of the piperidine and modifications of the piperidine moiety systematically to delineate structure-activity relationships influencing potency. Compounds were tested for growth-inhibitory activity against virulent M. tuberculosis. A selected set of compounds were also tested for its activity against Staphylococcus aureus. RESULTS: The compound with a norbornenylmethyl substituent at the N-1 position and N-benzyl-N-phenethylamine at the C-4 position of the piperidine (1) was the only active compound with a minimum inhibitory concentration (MIC) of 10 μM against M. tuberculosis. Compounds were not active against S. aureus. CONCLUSIONS: We were unable to derive any other analogs with MIC < 20 μM against M. tuberculosis. Therefore we conclude that the lack of activity is a liability in this series precluding it from further development. BioMed Central 2015-02-13 /pmc/articles/PMC4336482/ /pubmed/25881065 http://dx.doi.org/10.1186/s12952-015-0024-x Text en © Chandrasekera et al.; licensee BioMed Central. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Chandrasekera, N Susantha
Alling, Torey
Bailey, Mai
Korkegian, Aaron
Ahn, James
Ovechkina, Yulia
Odingo, Joshua
Parish, Tanya
The 4-aminopiperidine series has limited anti-tubercular and anti-staphylococcus aureus activity
title The 4-aminopiperidine series has limited anti-tubercular and anti-staphylococcus aureus activity
title_full The 4-aminopiperidine series has limited anti-tubercular and anti-staphylococcus aureus activity
title_fullStr The 4-aminopiperidine series has limited anti-tubercular and anti-staphylococcus aureus activity
title_full_unstemmed The 4-aminopiperidine series has limited anti-tubercular and anti-staphylococcus aureus activity
title_short The 4-aminopiperidine series has limited anti-tubercular and anti-staphylococcus aureus activity
title_sort 4-aminopiperidine series has limited anti-tubercular and anti-staphylococcus aureus activity
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4336482/
https://www.ncbi.nlm.nih.gov/pubmed/25881065
http://dx.doi.org/10.1186/s12952-015-0024-x
work_keys_str_mv AT chandrasekeransusantha the4aminopiperidineserieshaslimitedantitubercularandantistaphylococcusaureusactivity
AT allingtorey the4aminopiperidineserieshaslimitedantitubercularandantistaphylococcusaureusactivity
AT baileymai the4aminopiperidineserieshaslimitedantitubercularandantistaphylococcusaureusactivity
AT korkegianaaron the4aminopiperidineserieshaslimitedantitubercularandantistaphylococcusaureusactivity
AT ahnjames the4aminopiperidineserieshaslimitedantitubercularandantistaphylococcusaureusactivity
AT ovechkinayulia the4aminopiperidineserieshaslimitedantitubercularandantistaphylococcusaureusactivity
AT odingojoshua the4aminopiperidineserieshaslimitedantitubercularandantistaphylococcusaureusactivity
AT parishtanya the4aminopiperidineserieshaslimitedantitubercularandantistaphylococcusaureusactivity
AT chandrasekeransusantha 4aminopiperidineserieshaslimitedantitubercularandantistaphylococcusaureusactivity
AT allingtorey 4aminopiperidineserieshaslimitedantitubercularandantistaphylococcusaureusactivity
AT baileymai 4aminopiperidineserieshaslimitedantitubercularandantistaphylococcusaureusactivity
AT korkegianaaron 4aminopiperidineserieshaslimitedantitubercularandantistaphylococcusaureusactivity
AT ahnjames 4aminopiperidineserieshaslimitedantitubercularandantistaphylococcusaureusactivity
AT ovechkinayulia 4aminopiperidineserieshaslimitedantitubercularandantistaphylococcusaureusactivity
AT odingojoshua 4aminopiperidineserieshaslimitedantitubercularandantistaphylococcusaureusactivity
AT parishtanya 4aminopiperidineserieshaslimitedantitubercularandantistaphylococcusaureusactivity